Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is set to experience continued growth, with a projected revenue of $95.8M for FY2025 and $112.6M for FY2026, representing 27-29% YoY growth. The company's strong position in the market is supported by its Cell Processing platform's revenue of $93.0-94.0M. However, risks such as slower growth, inability to acquire new customers, sales fluctuations in emerging markets, and potential dilution risk should be monitored closely. Based on a comparable universe analysis, our 12-month price target for BioLife Solutions is $32 per share.

Bears say

BioLife Solutions is facing increasing competition in the CGT industry, with larger companies such as Thermo Fisher Scientific and Catalent entering the market. In addition, the company's reliance on a single product, CryoStor, leaves it vulnerable to changes in the market and potential disruptions. The company's negative earnings and low profit margins also raise concerns about its long-term sustainability and ability to generate significant returns for investors.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.